Process for the racemization of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid
By reacting and acidizing the basic compound in an organic solvent, the enantiomer purification process is simplified, the complex purification steps and solvent changes in the prior art are solved, and (5R)-4-[5- Enantiomer overtransfer and purification efficiency of (3,5-Dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazole-3-yl]-2-methyl-benzoic acid.
Patent Information
- Application Number
- CN201980084603.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2019-12-20
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2039-12-20
AI Technical Summary
Prior Art Enantiomer-pure or enantiomer-enriched (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isohydroxide in the isolation of enantiomers Zol-3-yl]-2-methyl-benzoic acid requires complex purification steps and solvent changes, and it is difficult to effectively remove by-products, affecting efficiency.
By reacting the mixture containing (R)-10BA and (S)-10BA with basic compounds in an organic solvent, the acidification treatment is carried out to separate the compound mixture, and the excess transfer and purification of enantiomers are achieved using a simple solvent system to avoid The use of phase transfer catalysts is carried out.
Simplification of enantiomer purification is achieved, reducing the complexity of the purification step, improving the purity and efficiency of the product, and avoiding the need for solvent changes.
Smart Images

Figure BDA0003122174670000011 
Figure BDA0003122174670000021 
Figure BDA0003122174670000041
Abstract
Description
[0001] The present invention relates to a process for the racemization of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid. Background Art
[0002] (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-2-methyl-benzamide (hereinafter referred to as flurellana) is a synthetic insecticide represented by the following formula (A).
[0003]
[0004] Fluorella is a systemically active ingredient that can be administered orally. It is reported that this active ingredient antagonizes the inhibition of GABA-gated chloride in the nervous system of several arthropods. Since fluorella does not show similar binding in the nervous system of mammals, it is suitable, for example, for the treatment of fleas, mites and ticks in mammals (e.g., dogs and cats).
[0005] Fluoranab is a racemic compound. It is reported that the (S)-enantiomer is the enantiomer that contributes greatly to the antiparasitic activity of the active ingredient. In view of this, the use of enantiomerically pure or enantiomerically enriched (S)-fluoranab is considered to be advantageous compared to racemic fluoranab. In order to prepare the enantiomerically pure or enantiomerically enriched (S)-fluoranab, enantiomerically pure or enantiomerically enriched (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid (IOBA) is a key intermediate in the synthesis of fluoranab, and the compound is represented by the following formula (1):
[0006]
[0007] Wherein the compound according to formula (1) can be prepared, for example, as described in Synthesis Example 3 of US 2007 / 0066617.
[0008] Since enantiomerically pure or enantiomerically enriched (S)-fluranabilone may be considered advantageous as an active ingredient, it would be desirable to isolate enantiomerically pure or enantiomerically enriched (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid (S)-IOBA.
[0009] When enantiomerically pure or enantiomerically enriched (S)-IOBA is separated from the racemate (IOBA), a fraction containing enantiomerically pure or enantiomerically enriched (R)-IOBA remains. The racemization of enantiomerically pure or enantiomerically enriched (R)-IOBA as a by-product of the above separation would be highly desirable compared to the preparation of IOBA.
[0010] WO 2014 / 090918 A1 describes the separation of another compound, racemic 3-methyl-5-[(5RS)-5-(3,4,5-trichlorophenyl)-5-(fluoromethyl)-4H-isoxazol-3-yl]thiophene-2-carboxylic acid (IOTA), into enantiomers by chiral column chromatography or by diastereoisomeric recrystallization. More specifically, the document describes the treatment of racemic IOTA with (R)-1-(4-methyl-phenyl)ethylamine in a ternary mixture of water, acetonitrile and 2-butanol to obtain a precipitate of the corresponding (S)-IOTA salt with a chiral purity of more than 95% after washing, which can be increased to more than 98% by a further recrystallization step. In addition, the supernatant solution of the precipitate of the corresponding (S)-IOTA salt is removed under vacuum to obtain a valuable by-product, an enriched (R)-IOTA mixture. This enriched (R)-IOTA mixture was racemized using aqueous sodium hydroxide in toluene as solvent mixture at 75°C in the presence of a phase transfer catalyst aqueous tributylmethylammonium chloride solution.
[0011] Prior art methods require a ternary mixture of solvents to precipitate the (S)-enantiomer compound. However, in order to racemize the remaining "by-product" enantiomer-enriched (R)-isoxazolinethiophenecarboxylic acid, this ternary solvent mixture must be changed. In addition, the prior art reactions require phase transfer catalysts, which are reported to be difficult to remove from the reaction mixture and / or the desired product, thereby possibly requiring complex purification steps.
[0012] Furthermore, it was found that treatment of racemic IOBA with (R)-1-(4-methylphenyl)ethanamine did not result in any precipitation of (S)-IOBA and therefore did not result in the resolution of enantiomerically pure or enantiomerically enriched (R)-IOBA.
[0013] Therefore, there still exists a need for the racemization of enantiomerically pure or enantiomerically enriched (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid which can preferably be applied in a simple and efficient manner.
[0014] It is therefore an object of the present invention to overcome one or more disadvantages of the above-mentioned processes. In particular, it is an object of the present invention to provide a process for the racemization of enantiomerically pure or enantiomerically enriched (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid without the need for complex purification steps. Another object of the present invention is to provide a process for the racemization of enantiomerically pure or enantiomerically enriched (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid using a simple solvent system.
[0015] The present invention unexpectedly solves at least one of the above objectives by providing a novel synthetic process for racemizing a mixture containing (R)-IOBA and (S)-IOBA, wherein the mixture has an enantiomeric excess of (R)-IOBA.
[0016] The present invention therefore provides a process for the racemization of a mixture containing (R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)]-2-methyl-benzoic acid according to formula (1a) and (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)]-2-methyl-benzoic acid according to formula (1b).
[0017]
[0018] wherein the mixture has an enantiomeric excess of the compound according to formula (1a), the process comprising the steps of:
[0019] (i) reacting the mixture with a basic compound in an organic solvent to obtain a reaction mixture. Summary of the invention
[0020] The present invention relates to a process for the racemization of a mixture containing (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid ((R)-IOBA) according to formula (1a) and (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid ((S)-IOBA) according to formula (1b), wherein the mixture contains an enantiomeric excess of the compound according to formula (1a).
[0021] According to the present application, racemization is considered to be a shift of the enantiomeric excess of a compound to a lower value. Racemization is not strictly considered to be a shift of the enantiomeric value to 0, which is the literal meaning of a racemate.
[0022] In general, the enantiomeric excess (ee) can be determined as described below. It may range from 1 to 100%, preferably from 10 to 100%, more preferably from 25 to 100%, in particular from 50 to 100%.
[0023] The enantiomeric excess of the compound according to formula (1a) means that the mixture comprises a higher amount of the compound according to formula (1a) than the compound according to formula (1b).
[0024] In one embodiment of the invention and / or its embodiments, the enantiomeric excess of the compound according to formula (1a) may be 100%; ie the mixture contains only the compound according to formula (1a) but no compound according to formula (1b).
[0025] The compounds according to formula (1a) and (1b) are the (R)-enantiomer or (S)-enantiomer of the compound (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1).
[0026] In step (i) of the process according to the present invention and / or any embodiment thereof, a mixture containing (R)-IOBA according to formula (1a) and (S)-IOBA according to formula (1b) is reacted with a basic compound in an organic solvent.
[0027] According to the present application, the basic compound in step (i) may be regarded as a base, which according to Broensted is a compound that can accept a hydrogen cation.
[0028] The basic compound may be an organic or inorganic basic compound.
[0029] Examples of organic basic compounds are diisopropylethylamine (DIPEA), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), 1,5-diazabicyclo[4.3.0]non-5-ene and 2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphine, and mixtures thereof.
[0030] In a preferred embodiment of the present invention and / or its embodiments, the basic compound in step (i) is an inorganic compound.
[0031] Examples of suitable inorganic basic compounds are alkali metal or alkaline earth metal phosphates, alkali metal or alkaline earth metal carbonates, alkali metal or alkaline earth metal hydrogencarbonates, alkali metal or alkaline earth metal hydroxides, alkali metal or alkaline earth metal oxides or mixtures thereof.
[0032] In a preferred embodiment of the present invention and / or its embodiments, the alkaline compound in step (i) can be selected from lithium oxide, sodium oxide, potassium oxide, cesium oxide, lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide, calcium hydroxide, barium hydroxide, magnesium oxide, calcium oxide, barium oxide, cesium carbonate and mixtures thereof. Preferred are sodium hydroxide, potassium hydroxide, cesium hydroxide, calcium hydroxide, barium hydroxide, barium oxide and mixtures thereof.
[0033] In a preferred embodiment of the present invention and / or its embodiments, the alkaline compound in step (i) may be selected from sodium hydroxide, potassium hydroxide, cesium hydroxide and mixtures thereof.
[0034] Other basic compounds suitable for use in step (i) are alkali metal or alkaline earth metal alkoxides. Suitable examples are sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium tert-butoxide and potassium tert-butoxide and mixtures thereof.
[0035] Step (i) of the method is carried out in an organic solvent. Organic solvents are well known to those skilled in the art. Although it does not contain any carbon atoms in accordance with the present application, water is considered an organic solvent.
[0036] Suitable organic solvents are, for example, water, alcohols such as propanol, cyclic ethers such as tetrahydrofuran and dioxane, aliphatic esters such as ethyl acetate, unsubstituted or substituted benzenes such as benzene and toluene.
[0037] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent is selected from water, alcohols having 1 to 5 carbon atoms, tetrahydrofuran, dioxane, toluene, ethyl acetate and mixtures thereof, more preferably selected from water, alcohols having 2 to 5 carbon atoms, dioxane, toluene and mixtures thereof.
[0038] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is an alcohol with 1 to 5 carbon atoms. The alcohol is preferably a monohydric alcohol, i.e. the organic solvent carries only one hydroxyl group. It is further preferred that the organic solvent carries only a hydroxyl functional group. In other words, the alcohol does not carry any other functional groups except (one) hydroxyl group. In addition, the alcohol with 1 to 5 carbon atoms used as the organic solvent contains only hydrogen, oxygen and carbon atoms. Suitably, the alcohol is not further substituted.
[0039] Examples of alcohols having 1 to 5 carbon atoms used as organic solvents are methanol, ethanol, 1-propanol, 2-propanol, cyclopropanol, 1-butanol, 2-butanol, cyclobutanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, 3-pentanol, cyclopentanol, 2-methyl-1-butanol, 3-methyl-1-butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, 2,2-dimethyl-1-propanol and mixtures thereof.
[0040] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent is an alcohol having 1 to 5 carbon atoms selected from the group consisting of ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 1-pentanol, 2-pentanol, 3-pentanol and mixtures thereof. More preferably, the organic solvent is an alcohol having 2 to 5 carbon atoms selected from the group consisting of ethanol, 1-propanol, 2-propanol, 1-butanol, 1-pentanol and mixtures thereof.
[0041] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol.
[0042] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is sodium hydroxide.
[0043] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is potassium hydroxide.
[0044] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is cesium hydroxide.
[0045] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is calcium hydroxide.
[0046] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is barium hydroxide.
[0047] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is ethanol and the alkaline compound is barium oxide.
[0048] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol.
[0049] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is sodium hydroxide.
[0050] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is potassium hydroxide.
[0051] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is cesium hydroxide.
[0052] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is calcium hydroxide.
[0053] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is barium hydroxide.
[0054] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 1-propanol and the alkaline compound is barium oxide.
[0055] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 2-propanol.
[0056] In a particularly preferred embodiment of the present invention and / or its embodiments, in step (i), the organic solvent is 2-propanol and the alkaline compound is sodium hydroxide.
[0057] In a particularly preferred embodiment of the present invention and / or its embodiments, in step (i), the organic solvent is 2-propanol and the alkaline compound is potassium hydroxide.
[0058] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 2-propanol and the alkaline compound is cesium hydroxide.
[0059] In a particularly preferred embodiment of the present invention and / or its embodiments, in step (i), the organic solvent is 2-propanol and the alkaline compound is calcium hydroxide.
[0060] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (i) is 2-propanol and the alkaline compound is barium hydroxide.
[0061] In a particularly preferred embodiment of the present invention and / or its embodiments, in step (i), the organic solvent is 2-propanol and the basic compound is barium oxide.
[0062] In a preferred embodiment of the present invention and / or its embodiments, the molar ratio of the mixture comprising (R)-IOBA according to formula (1a) and (S)-IOBA according to formula (1b) to the basic compound is from 1:1 to 1:10, more preferably from 1:2 to 1:8, in particular from 1:3 to 1:6, especially about 1:4.5.
[0063] In a preferred embodiment of the present invention and / or its embodiments, step (i) is carried out at an elevated temperature. The elevated temperature is a temperature from 23°C (room temperature) to the boiling point of the organic solvent. In a preferred embodiment of the present invention and / or other embodiments, step (i) is carried out at the boiling point temperature of the organic solvent. All temperatures as indicated herein and related to boiling point temperatures or boiling points refer to temperatures measured at a normal pressure of 101 kPa.
[0064] Furthermore, the reaction of step (i) may preferably be subjected to mechanical motion, such as stirring or ultrasonic treatment.
[0065] In a preferred embodiment of the present invention and / or its embodiments, the duration of step (i) may be between 30 minutes and 48 hours, preferably between 2 hours and 36 hours, in particular between 4 hours and 24 hours.
[0066] In a preferred embodiment of the present invention and / or its embodiments, the method of the present invention further comprises the following steps
[0067] (ii) acidifying the reaction mixture from step (i), thereby obtaining a resulting mixture
[0068] (iii) separating the resulting mixture into a compound mixture and a supernatant.
[0069] In step (ii), the reaction mixture from step (i) may be acidified, preferably with an aqueous solution of a Bronsted acid. In a preferred embodiment of the present invention and / or its embodiments, the acid has a pKa of 3.5 or less, preferably a pKa of 3.0 or less, more preferably a pKa of 2.5 or less, in particular a pKa of 2.0 or less.
[0070] Examples of suitable acids having a pKa of 3.5 or less are hydrogen chloride (the corresponding acid is hydrochloric acid), hydrogen bromide, hydrogen iodide, nitric acid, sulfuric acid, sodium or potassium hydrogen sulfate, phosphoric acid, trichloroacetic acid, fumaric acid, maleic acid, oxalic acid, citric acid, lactic acid, 2-chlorobenzoic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and mixtures thereof.
[0071] The Bronsted acid may be an organic acid or an inorganic acid.
[0072] Examples of organic acids that can be used as Bronsted acids are fumaric acid, maleic acid, oxalic acid, citric acid, lactic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid and mixtures thereof. Preferred are methanesulfonic acid, ethanesulfonic acid and p-toluenesulfonic acid, especially methanesulfonic acid and p-toluenesulfonic acid.
[0073] Examples of inorganic acids which can be used as Bronsted acids are hydrogen chloride (the corresponding acid is hydrochloric acid), hydrogen bromide, hydrogen iodide, nitric acid, sulfuric acid, sodium or potassium hydrogen sulfate, phosphoric acid and mixtures thereof.
[0074] In a preferred embodiment of the present invention and / or its embodiments, the acidic aqueous solution in step (ii) is an inorganic acid solution, preferably hydrogen chloride, hydrogen bromide, sulfuric acid, sodium or potassium hydrogen sulfate, phosphoric acid and mixtures thereof, more preferably hydrogen chloride, sodium or potassium hydrogen sulfate, phosphoric acid and mixtures thereof, especially hydrogen chloride, potassium hydrogen sulfate or phosphoric acid, especially potassium hydrogen sulfate.
[0075] Step (ii) of acidifying the solution from step (i) may preferably be performed under cooling, preferably at a temperature of 5°C to 20°C, more preferably about 10°C.
[0076] Further, step (ii) may preferably be performed under mechanical motion such as stirring or ultrasonic treatment.
[0077] In step (iii), a compound mixture can be separated. The compound mixture contains (R)-IOBA according to formula (1a) and (S)-IOBA according to formula (1b), wherein the amount of (S)-IOBA according to formula (1b) in the mixture is increased compared to the amount of (S)-IOBA in the mixture of step (i). In a preferred embodiment of the present invention and / or its embodiments, the obtained compound is a racemate of IOBA, i.e. (R)-IOBA according to formula (1a) and (S)-IOBA according to formula (1b) are present in a molar ratio of about 1:1.
[0078] Separation can include known methods for separating solid organic compounds, particularly solid organic acids, from acidic aqueous solutions. Separation can include methods such as decanting or pouring out the solution, optionally with preceding centrifugal steps and filtering. In addition, separation can be performed by extracting the desired compound from the acidic aqueous solution.
[0079] In a preferred embodiment of the present invention and / or its embodiments, in step (iii), the separation of the obtained compound mixture is carried out by extraction with an organic solvent. Organic solvents are well known to those skilled in the art. In step (iii), the extraction can preferably be carried out in an aprotic organic solvent. Suitable organic solvents for step (iii) of the present invention are, for example, toluene, benzene, xylene, ethyl acetate, hexane, heptane, octane, cyclic and acyclic alkyl ethers, chlorobenzene, cyclohexane, methylcyclohexane, methylene chloride, dichloroethane, chloroform, trichloroethane, tetrachloroethane, dimethoxyethane, diethoxyethane and combinations thereof. Ethyl acetate, toluene, methylene chloride and chloroform are preferred, particularly ethyl acetate and toluene, particularly ethyl acetate.
[0080] The extraction step preferably comprises adding an organic solvent to the acidified aqueous solution from step (ii), mixing the two liquids and separating the organic solvent phase from the acidic aqueous solution. This process may preferably be repeated, preferably two to four times. The organic phases may then preferably be combined and dried. Drying may be carried out using any known drying agent such as sodium sulfate or magnesium sulfate. After drying, the drying agent may be separated from the organic phase, preferably by filtration.
[0081] Furthermore, step (iii) preferably comprises removing the organic solvent from the organic phase, preferably from the combined organic phases. The removal of the organic solvent may preferably be carried out at a temperature of 23°C to 50°C, preferably about 40°C and / or under a reduced pressure of 1 kPa to 90 kPa, preferably about 10 kPa.
[0082] In a preferred embodiment of the present invention and / or its embodiments, step (i) is carried out in the absence of a phase transfer catalyst. A phase transfer catalyst can be considered as a substance that promotes the migration of reactants from one phase to another phase where the reaction occurs. A phase transfer catalyst can also be considered as a heterogeneous catalyst. By avoiding the use of a phase transfer catalyst, the purity of the desired product can be improved, in this case the compound produced from step (iii), because the phase transfer catalyst is usually difficult to remove from the reaction mixture and / or the desired product.
[0083] In a preferred embodiment of the present invention and / or its embodiments, the method of the present invention further comprises the following previous steps:
[0084] (a) reacting (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid with a compound of formula (2A), (2B) or (2C)
[0085]
[0086] wherein R is an alkyl group having 1 or 2 carbon atoms,
[0087]
[0088] Wherein X is Cl or Br;
[0089] In the selected polar E T (30) is an organic solvent with a polarity between 180 and 230 kJ / mol. T (30) is reacted in an organic solvent having a concentration of between 130 and 175 kJ / mol and a mixture thereof to form a precipitate and a supernatant solution, and
[0090] (b) separating the supernatant solution containing (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1a) and (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1b) from the precipitate and the supernatant solution
[0091]
[0092] In a preferred embodiment of the present invention and / or its embodiments, the above steps (a) and (b) may be performed sequentially.
[0093] In a preferred embodiment of the present invention and / or its embodiments, steps (a) and (b) and step (i) may be performed continuously.
[0094] In a preferred embodiment of the present invention and / or its embodiments, steps (a) and (b) and steps (i), (ii) and (iii) may be performed continuously.
[0095] In a preferred embodiment of the present invention and / or its embodiments, in step (a) of the method according to the present invention and / or any embodiment thereof, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid is reacted with a compound of formula (2A), (2B) or (2C) in a reaction mixture selected from the group consisting of polar E T (30) is an organic solvent with a polarity of 180 to 230 kJ / mol. T (30) is reacted in an organic solvent having a concentration of between 130 and 175 kJ / mol and a mixture thereof to form a precipitate and a supernatant solution.
[0096] In formula (2A), the residue R is an alkyl group having one or two carbon atoms.
[0097] In a preferred embodiment of the present invention and / or its embodiments, the residue R is an alkyl radical having one carbon atom, ie the residue R is a methyl radical. The corresponding base or basic compound is (S)-1-phenylethylamine.
[0098] In an alternative preferred embodiment of the present invention and / or its embodiments, the residue R is an alkyl group with two carbon atoms, i.e. the residue R is an ethyl group. The corresponding base or basic compound is (S)-1-amphetamine.
[0099] The compound according to formula (2B) is (R)-1-phenyl-2-methyl-propylamine.
[0100] In formula (2C), the residue X is Cl or Br.
[0101] In a preferred embodiment of the present invention and / or its embodiments, the residue X in formula (2C) is Cl and the corresponding base or basic compound is (R)-1-(4-chlorophenyl)-ethylamine.
[0102] In a more preferred embodiment, the residue X in formula (2C) is Br and the corresponding base or basic compound is (R)-1-(4-bromophenyl)-ethylamine.
[0103] In a preferred embodiment of the present invention and / or its embodiments, the compound of formula (2A), (2B) or (2C) is selected from (S)-1-phenyl-propylamine, (R)-1-phenyl-2-methyl-propylamine, (R)-1-(4-chlorophenyl)-ethylamine and (R)-1-(4-bromophenyl)-ethylamine.
[0104] In a preferred embodiment of the present invention and / or its embodiments, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid is reacted in step (i) with a compound of formula (2A), (2B) or (2C) in a molar ratio between 1:0.4 and 1:5, preferably between 1:0.5 and 1:3, more preferably between 1:0.6 and 1:2, in particular between 1:0.7 and 1:1.
[0105] In step (a), the organic solvent is a liquid compound that dissolves, preferably completely dissolves, a substance to form a solution. Examples of organic solvents are well known in the art. Organic solvents can be classified, for example, by their boiling point (high boiling point solvents or low boiling point solvents), their acidity / basicity (acidic or basic solvents) and / or their polarity (polar and non-polar solvents).
[0106] E T (30) The values are considered to represent the polarity of different solvents (see, for example, Jose P. Ceron-Carrasco et al.: "Solvent polarity scales: determination of new E T (30)values for 84 organicsolvents", Research Article; Journal of Physical Organic Chemistry, 2014, 27, pp. 512-518). E TThe (30) value is determined with the aid of the negative solvatochromic dye 2,6-diphenyl-4-(2,4,6-triphenylpyridin-1-ium-1-yl)phenolate (also known as Betaine 30 or Reichhardt dye). Betaine 30 is represented by the compound according to the following formula (B):
[0107]
[0108] More specifically, E T (30) values are determined by Betaine 30 in the corresponding solvent via the longest wavelength VIS / NIR adsorption band. T (30) values are considered to correspond to high polarity of the solvent, while low E T (30) indicates a low polarity of the solvent. T (30)The higher the value, the greater the polarity of the solvent, and vice versa. T (30) The value is also defined as the molar electron excitation energy, calculated as follows
[0109]
[0110] where λ max It is the long wavelength absorption band in the visible / near infrared region of Betaine 30 measured at 25°C and 101 kPa in the corresponding solvent.
[0111] In a preferred embodiment of the present invention and / or its embodiments, in step (a) of the method of the present invention, the organic solvent E T (30) values are between 170 and 230 kJ / mol, preferably between 180 and 225 kJ / mol, more preferably between 190 and 220 kJ / mol, in particular between 200 and 218 kJ / mol.
[0112] E T(30) Examples of organic solvents having values between 170 and 230 kJ / mol are pyridines such as 2-fluoropyridine and 2,6-difluoropyridine; alcohols such as ethanol, 1-propanol, 2-propanol, cyclopropanol, 1-butanol, 2-butanol, cyclobutanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, 3-pentanol, cyclopentanol, 2-methyl-1-butanol, 3-methyl- 1-Butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, 2,2-dimethyl-1-propanol, allyl alcohol, 2-methoxyethanol, 2-ethoxyethanol, 2-(n-butoxy)ethanol, 2-phenoxyethanol, cyclohexanol, 1-hexanol, 1-heptanol, 1-octanol, 1-nonanol, 1-decanol, 2-phenylethanol, benzyl alcohol, 2-chloroethanol, 1,1,1-trifluoro-2-(trifluoromethyl)ethanol 1,1,1-trifluoro-2-(trifluoromethyl)pent-4-en-2-ol, 2,2,2-trifluoro-1-phenylethanol, 1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-ol; ketones such as 1,1,1-trichloroacetone; esters and lactones such as 4-butyrolactone and ethyl propiolate; amides and cyanamides such as N,N-dimethylformamide, N,N-dimethylcyanamide, pyrrolidine- 2-ketone, N-methylpropionamide, N-ethylacetamide, N-methylacetamide, N-methylformamide; nitriles such as n-propionitrile, 3-methoxypropionitrile, acetonitrile, chloroacetonitrile; nitroalkanes such as nitromethane and nitroethane; aromatic amines such as aniline; phosphorus compounds such as trimethyl phosphate; and sulfur-containing compounds such as tetrahydro-3-methylthiophene-1,1-dioxide, tetramethylene sulfoxide, dimethyl sulfoxide and vinyl sulfite.
[0113] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is an alcohol selected from the group consisting of ethanol, 1-propanol, 2-propanol, cyclopropanol, 1-butanol, 2-butanol, cyclobutanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, 3-pentanol, cyclopentanol, 2-methyl-1-butanol, 3-methyl-1-butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, 2,2-dimethyl-1-propanol, allyl alcohol. alcohol, 2-methoxyethanol, 2-ethoxyethanol, 2-(n-butoxy)ethanol, 2-phenoxyethanol, cyclohexanol, 1-hexanol, 1-octanol, 1-decanol, 2-phenylethanol, benzyl alcohol, 2-chloroethanol, 1,1,1-trifluoro-2-(trifluoromethyl)pentan-2-ol, 1,1,1-trifluoro-2-(trifluoromethyl)pent-4-en-2-ol, 2,2,2-trifluoro-1-phenylethanol, 1,1,1,3,3,3-hexafluoro-2-phenylpropan-2-ol and mixtures thereof.
[0114] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is an alcohol with 2 to 8 carbon atoms. The alcohol is preferably a monohydric alcohol, i.e. the organic solvent carries only one hydroxyl group. Further preferred organic solvents carry only hydroxyl functional groups. In other words, except (one) hydroxyl group, the alcohol does not carry any other functional groups. In addition, the alcohol with 2 to 8 carbon atoms used as an organic solvent contains only hydrogen, oxygen and carbon atoms. Suitably, the alcohol is not further substituted.
[0115] Examples of alcohols having 2 to 8 carbon atoms used as organic solvents are ethanol, 1-propanol, 2-propanol, cyclopropanol, 1-butanol, 2-butanol, cyclobutanol, 2-methyl-1-propanol, 2-methyl-2-propanol, 1-pentanol, 2-pentanol, 3-pentanol, cyclopentanol, 2-methyl-1-butanol, 3-methyl-1-butanol, 3-methyl-2-butanol, 2-methyl-2-butanol, 2,2-dimethyl-1-propanol, 1-hexanol, 1-heptanol, 1-octanol, and mixtures thereof.
[0116] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is an alcohol having 2 to 8 carbon atoms selected from the group consisting of ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, 1-pentanol, 2-pentanol, 3-pentanol, 1-hexanol and mixtures thereof, more preferably an organic solvent is an alcohol having 2 to 8 carbon atoms selected from the group consisting of ethanol, 2-propanol, 1-butanol, 1-pentanol, 1-hexanol, 1-heptanol and mixtures thereof.
[0117] In a particularly preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is ethanol. In an alternative preferred embodiment, the organic solvent in step (a) is 2-propanol. In an alternative preferred embodiment, the organic solvent in step (a) is 1-butanol. In an alternative preferred embodiment, the organic solvent in step (a) is 1-pentanol. In an alternative preferred embodiment, the organic solvent in step (a) is 1-hexanol.
[0118] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is not an amide or a cyanamide.
[0119] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is not a sulfur-containing compound.
[0120] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is methyl and the organic solvent is selected from ethanol, 2-propanol, 1-butanol, 1-pentanol, 1-hexanol, 1-heptanol, 1-octanol and mixtures thereof.
[0121] Alternatively, preferably, in step (a), the residue R of formula (2A) is methyl and the organic solvent is ethanol, or the residue R of formula (2A) is methyl and the organic solvent is 2-propanol.
[0122] Alternatively, preferably, in step (a), the residue R of formula (2A) is methyl and the organic solvent is 1-butanol, or the residue R of formula (2A) is methyl and the organic solvent is 1-pentanol, or the residue R of formula (2A) is methyl and the organic solvent is 1-hexanol.
[0123] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is ethyl and the organic solvent is selected from ethanol, 2-propanol, 1-butanol, 1-pentanol, 1-hexanol and mixtures thereof.
[0124] Alternatively, preferably, in step (a), the residue R of formula (2A) is ethyl and the organic solvent is ethanol, or the residue R of formula (2A) is ethyl and the organic solvent is 2-propanol.
[0125] Alternatively, preferably, in step (a), the residue R of formula (2A) is ethyl and the organic solvent is 1-butanol, or the residue R of formula (2A) is ethyl and the organic solvent is 1-pentanol, or the residue R of formula (2A) is ethyl and the organic solvent is 1-hexanol.
[0126] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is ethanol, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is 2-propanol, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is 1-butanol, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is 1-pentanol, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is 1-hexanol.
[0127] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl (chloride) or Br (bromide).
[0128] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl and the organic solvent is 2-propanol.
[0129] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from ethanol, 2-propanol, 1-butanol, 1-pentanol and mixtures thereof.
[0130] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue X of formula (2C) is Br and the organic solvent is ethanol, or the residue R of formula (2C) is Br and the organic solvent is 2-propanol, or the residue R of formula (2C) is Br and the organic solvent is 1-butanol, or the residue R of formula (2C) is Br and the organic solvent is 1-pentanol.
[0131] In a preferred embodiment of the present invention and / or its embodiments, in step (a), (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid and a compound of formula (2A), (2B) or (2C) are reacted at a polarity E T (30) reacts in an organic solvent between 180 and 230 kJ / mol to form a precipitate and a supernatant solution. Thus, in an organic solvent, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methylbenzoic acid, preferably (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid and a compound of formula (2A), (2B) or (2C) interact with each other to form a precipitate product and a supernatant solution. In other words, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and the compound of formula (2A), (2B) or (2C) react with each other to form a solid product, which can be precipitated from the reaction mixture, preferably completely precipitated, while the supernatant solution is still present. The supernatant solution preferably contains a small portion of unreacted (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and preferably a major portion of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid.
[0132] In an alternative preferred embodiment of the present invention and / or embodiments, the organic solvent in step (a) of the process of the present invention has an E of T (30) The values are between 130 and 175 kJ / mol.
[0133] E T(30) Examples of solvents having values between 130 and 175 kJ / mol are aliphatic, cycloaliphatic or aromatic ethers, such as ethylene glycol dimethyl ether, triethylene glycol dimethyl ether, 1,2-dimethoxyethane, di-n-butyl ether, di-tert-butyl ether, diisopropyl ether, n-butyl methyl ether, methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, tetrahydropyran, 2,2,5,5-tetramethyltetrahydropyran, tetrahydrofuran, tetrahydro-2-methylfuran, 2,2,5,5-tetramethyltetrahydrofuran, benzyl methyl ether, dibenzyl ether, anisole, 3-methylanisole and phenethyl ether. ; Aromatic hydrocarbons and pyridines such as benzene, toluene, m-xylene and mesitylene; halogenated aromatic hydrocarbons such as chlorobenzene, 1,3-dichlorobenzene, bromobenzene and 1,3-dibromobenzene and pyridine; aliphatic esters such as methyl formate, methyl acetate, methyl propionate, methyl butyrate, methyl hexanoate, ethyl formate, ethyl acetate, ethyl propionate, ethyl benzoate and butyl acetate; aliphatic, alicyclic or aromatic amines such as diethylamine, triethylamine, diisopropylamine, morpholine, piperidine; halogenated alkanes such as chloroform, tetrachloromethane, 1,1-dichloroethane, 1,2-dichloroethane and 1,1,2,2-tetrachloroethane and mixtures thereof.
[0134] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is T (30) The value is between 132 and 175 kJ / mol, preferably between 134 and 174 kJ / mol, more preferably between 135 and 170 kJ / mol, in particular between 140 and 165, and even more in particular between 134 and 160 kJ / mol.
[0135] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is an aliphatic or alicyclic ether such as ethylene glycol dimethyl ether, triethylene glycol dimethyl ether, 1,2-dimethoxyethane, di-n-butyl ether, di-tert-butyl ether, diisopropyl ether, etc., n-butyl methyl ether, methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, tetrahydrofuran, tetrahydro-2-methylfuran; aromatic hydrocarbons such as benzene, toluene, m-xylene, mesitylene, halogenated aromatic hydrocarbons such as chlorobenzene, bromobenzene; aliphatic esters such as methyl acetate, methyl propionate, methyl butyrate, ethyl acetate, ethyl propionate, ethyl benzoate, butyl acetate; aliphatic amines such as diethylamine, triethylamine, diisopropylamine; halogenated alkanes such as chloroform, tetrachloromethane, 1,1-dichloroethane and 1,2-dichloroethane and mixtures thereof.
[0136] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0137] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is methyl tert-butyl ether. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is cyclopentyl methyl ether. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is tetrahydrofuran. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is dioxane. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is chlorobenzene. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is toluene. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is meta-xylene. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is mesitylene. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is ethyl acetate. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is butyl acetate. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is triethylamine. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is chloroform. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is 1,2-dichloroethane.
[0138] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in step (a) is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0139] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is methyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0140] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is methyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0141] In a preferred embodiment of the present invention and / or its embodiments, the R residue of formula (2A) in step (a) is methyl and the organic solvent is selected from dioxane, chlorobenzene, toluene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0142] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue R of formula (2A) is methyl and the organic solvent is methyl tert-butyl ether, or the residue R of formula (2A) is methyl and the organic solvent is cyclopentyl methyl ether, or the residue R of formula (2A) is methyl and the organic solvent is tetrahydrofuran, or the residue R of formula (2A) is methyl and the organic solvent is dioxane, or the residue R of formula (2A) is methyl and the organic solvent is chlorobenzene, or the residue R of formula (2A) is methyl and the organic solvent is toluene , or the residue R of formula (2A) is methyl and the organic solvent is m-xylene, or the residue R of formula (2A) is methyl and the organic solvent is mesitylene, or the residue R of formula (2A) is methyl and the organic solvent is ethyl acetate, or the residue R of formula (2A) is methyl and the organic solvent is butyl acetate, or the residue R of formula (2A) is methyl and the organic solvent is triethylamine, or the residue R of formula (2A) is methyl and the organic solvent is chloroform, or the residue R of formula (2A) is methyl and the organic solvent is 1,2-dichloroethane.
[0143] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is ethyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0144] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is ethyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0145] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is ethyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, 1,2-dichloroethane and mixtures thereof.
[0146] In a preferred embodiment of the present invention and / or its embodiments, the residue R of formula (2A) in step (a) is ethyl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, chlorobenzene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, 1,2-dichloroethane and mixtures thereof.
[0147] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue R of formula (2A) is ethyl and the organic solvent is methyl tert-butyl ether, or the residue R of formula (2A) is ethyl and the organic solvent is cyclopentyl methyl ether, or the residue R of formula (2A) is ethyl and the organic solvent is tetrahydrofuran, or the residue R of formula (2A) is ethyl and the organic solvent is dioxane, or the residue R of formula (2A) is ethyl and the organic solvent is chlorobenzene, or the residue R of formula (2A) is ethyl and the organic solvent is toluene , or the residue R of formula (2A) is ethyl and the organic solvent is m-xylene, or the residue R of formula (2A) is ethyl and the organic solvent is mesitylene, or the residue R of formula (2A) is ethyl and the organic solvent is ethyl acetate, or the residue R of formula (2A) is ethyl and the organic solvent is butyl acetate, or the residue R of formula (2A) is ethyl and the organic solvent is triethylamine, or the residue R of formula (2A) is ethyl and the organic solvent is chloroform, or the residue R of formula (2A) is ethyl and the organic solvent is 1,2-dichloroethane.
[0148] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is tetrahydrofuran, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is dioxane, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is toluene, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is ethyl acetate, or the chiral base is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is 1,2-dichloroethane.
[0149] In a preferred embodiment of the present invention and / or its embodiments, the chiral base in step (a) is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, tetrahydrofuran, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0150] In a preferred embodiment of the present invention and / or its embodiments, the chiral base in step (a) is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0151] In a preferred embodiment of the present invention and / or its embodiments, the chiral base in step (a) is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is selected from chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0152] In a preferred embodiment of the present invention and / or its embodiments, the chiral base in step (a) is (R)-1-phenyl-2-methyl-propylamine (Formula 2B) and the organic solvent is selected from chlorobenzene, toluene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0153] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl (chloride) or Br (bromide).
[0154] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl and the organic solvent is selected from tetrahydrofuran, dioxane, toluene, ethyl acetate and mixtures thereof.
[0155] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0156] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue X of formula (2C) is Cl and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0157] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl and the organic solvent is selected from chlorobenzene, toluene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0158] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Cl and the organic solvent is selected from toluene, ethyl acetate and mixtures thereof.
[0159] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue R of formula (2C) is chloride and the organic solvent is tetrahydrofuran, the residue R of formula (2C) is chloride and the organic solvent is dioxane, the residue R of formula (2C) is chloride and the organic solvent is toluene, or the residue R of formula (2C) is chloride and the organic solvent is ethyl acetate.
[0160] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from tetrahydrofuran, dioxane, toluene, ethyl acetate and mixtures thereof.
[0161] In a preferred embodiment of the present invention and / or its embodiments, in step (a), the residue R of formula (2C) is a bromide and the organic solvent is tetrahydrofuran, the residue R of formula (2C) is a bromide and the organic solvent is dioxane, the residue R of formula (2C) is a bromide and the organic solvent is toluene, or the residue R of formula (2C) is a bromide and the organic solvent is ethyl acetate.
[0162] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, dioxane, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0163] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from methyl tert-butyl ether, cyclopentyl methyl ether, chlorobenzene, toluene, m-xylene, mesitylene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0164] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from chlorobenzene, toluene, ethyl acetate, butyl acetate, triethylamine, chloroform, 1,2-dichloroethane and mixtures thereof.
[0165] In a preferred embodiment of the present invention and / or its embodiments, the residue X of formula (2C) in step (a) is Br and the organic solvent is selected from toluene, ethyl acetate and mixtures thereof.
[0166] In a preferred embodiment of the present invention and / or its embodiments, in step (a), (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid and a compound of formula (2A), (2B) or (2C) are reacted at a polarity E T (30) reacts in an organic solvent between 130 and 175 kJ / mol to form a precipitate and a supernatant solution. Thus, in an organic solvent, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably (S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and a compound of formula (2A), (2B) or (2C) interact with each other to form a precipitate product and a supernatant solution. In other words, (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and the compound of formula (2A), (2B) or (2C) react with each other to form a solid product, which can be precipitated from the reaction mixture, preferably completely precipitated, while the supernatant solution is still present. The supernatant solution preferably contains a small portion of unreacted (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, and preferably a major portion of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid.
[0167] The reaction of (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid with the compound of formula (2A), (2B) or (2C) can be carried out at any temperature as long as the solvent is in a liquid state. For example, in step (a), the reaction can be carried out at a temperature between 4 and 65°C, preferably between 10 and 55°C, also preferably between 15 and 45°C, preferably between 20 and 40°C, preferably between 25 and 35°C, and most preferably at a temperature of about 23°C (also known as room temperature).
[0168] In a preferred embodiment of the present invention and / or its embodiments, step (a) comprises heating (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid and a compound of formula (2A), (2B) or (2C) to an elevated temperature. The elevated temperature is a temperature from 23°C (room temperature) to the boiling temperature of the organic solvent, preferably from 30°C to the boiling temperature of the organic solvent minus 5°C, more preferably from 40°C to the boiling temperature of the organic solvent minus 20°C. This means that if ethanol with a boiling temperature or a boiling point of 78°C is used as an organic solvent, the reaction in step (i)) may preferably be carried out at a temperature of 23°C to 78°C, preferably 30°C to 73°C, more preferably 40°C to 68°C. All temperatures as indicated herein and related to boiling temperatures or boiling points relate to temperatures measured at normal pressure of 101 kPa.
[0169] Further, step (a) preferably comprises cooling the reaction mixture of said step. In the case where step (a) does not comprise heating the reaction mixture to an elevated temperature, the reaction mixture may be cooled to 0°C to 20°C, preferably about 10°C. In the case where step (i) comprises heating the reaction mixture to an elevated temperature, the reaction mixture may preferably be cooled to 0°C to 40°C, preferably 10°C to 30°C, in particular to about 23°C (room temperature). By cooling the reaction mixture, the product obtained forms a precipitate and a supernatant solution, wherein the supernatant solution preferably comprises (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, preferably in enantiomeric excess.
[0170] Furthermore, the reaction of step (a) may preferably be subjected to mechanical motion, such as stirring or ultrasonic treatment.
[0171] In a preferred embodiment of the present invention and / or its embodiments, the duration of step (a) may be between 15 minutes and 24 hours, preferably between 30 minutes and 12 hours, in particular between 1 hour and 6 hours.
[0172] In step (b), the supernatant solution from step (a) is separated from the precipitate. The supernatant solution is a liquid and can be separated from the solid precipitate by any method that separates a liquid from a solid. Examples of these methods are decantation or pouring off the supernatant solution, optionally with a previous centrifugation step and filtration.
[0173] In a preferred embodiment of the present invention and / or its embodiments, in step (b), separation of the supernatant solution from the precipitate is performed by filtration. As used herein, filtration is a mechanical or physical operation that separates solids (in this case, precipitates) from liquids (in this case, supernatant solutions) by a medium through which only fluids can pass. Such a medium may be referred to as a filter or sieve, preferably a filter. Examples of suitable filters are suction filters, filter presses or pleated filters, preferably suction filters.
[0174] In a preferred embodiment of the present invention and / or its embodiments, the organic solvent in steps (a) and (i) is the same. As for the definition of organic solvent, it is the same as described under step (a) of the inventive method. In a preferred embodiment of the present invention and / or its embodiments, the organic solvent is 2-propanol.
[0175] Surprisingly, it was found that the separation of (S)-IOBA and the racemization of the resulting supernatant solution containing excess (R)-IOBA can be carried out in the same solvent, i.e. no solvent change is required to carry out the racemization step, which can be regarded as a step for recovering the valuable (S)-enantiomer of IOBA from a solution having an enantiomeric excess of the (R)-enantiomer of IOBA.
[0176] According to the present application, enantiomeric excess (ee) is defined as the absolute difference between the mole fractions of each enantiomer and can be expressed as the enantiomeric excess percentage, which is calculated according to the following formula:
[0177] ee=(|F R -F S |x100)%
[0178] in
[0179] F R is the mole fraction of the (R)-enantiomer, and
[0180] F S is the mole fraction of the (S)-enantiomer
[0181] The amount and therefore the molar fraction of the corresponding enantiomer can be determined by methods known in the art, for example by the numerical value of the optical purity of the compound in question, by chiral column chromatography (chiral LC or SFC) or by NMR-spectroscopy in the presence of a chiral shift reagent. In the present application, the chiral LC molar fraction of the corresponding enantiomer is determined by chiral LC. Another possibility is to convert (S)-IOBA into diastereomeric amides or esters using chiral amines or alcohols and determine the ee% by LC.
[0182] The present invention will now be further described by the following non-limiting examples: Example
[0183] Example 1
[0184] A flask equipped with a condenser and a thermometer was charged with 2-propanol (12.5 ml) and water (0.85 ml). Solid potassium hydroxide (0.671 g, 11.96 mmol) was dissolved in the solvent, and (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (1 g, 2.391 mmol) having 87.2% ee was added at 23°C (room temperature). The mixture was heated to 80°C.
[0185] 50 μl samples were taken after 1 hour, 2 hours and 16 hours to determine the degree of racemization. Each sample was treated as follows: 4 The solution (1 ml, 2.3 M) was quenched and extracted twice with ethyl acetate (once with 2 ml and once with 1 ml). The combined organic phases were concentrated under reduced pressure. The residue was dried under oil pump vacuum and dissolved in a mixture of isohexane:ethanol 1:1 (1 ml).
[0186] The enantiomeric excess of (R)-IOBA obtained was 84.8% after one hour, 84.5% after two hours and 64% after 16 hours.
[0187] Example 2
[0188] In a flask equipped with a condenser and a thermometer, 2-propanol (6.67 ml) was charged and (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (1 g, 2.391 mmol) having 86.4% ee was dissolved. Sodium hydroxide (0.393 g, 9.83 mmol) beads were added at 40° C. and the mixture was heated to reflux, thereby obtaining a yellow suspension.
[0189] 50 μl samples were taken after 2 hours, 4 hours and 20 hours to determine the degree of racemization. Each sample was processed as described in Example 1.
[0190] The enantiomeric excess of the resulting (R)-IOBA was 62.4% after two hours, 85.0% after four hours and 31.8% after 20 hours.
[0191] Example 3
[0192] A solution of (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (50 mg, 0.120 mmol) in 2-propanol (299 μl) with >99% ee was incubated with a solution of potassium hydroxide in 2-propanol (20.38 μl, 0.359 mmol) in a 1 ml conical vial. The mixture was heated to 90° C. overnight.
[0193] A 100 μL sample of the reaction mixture was concentrated to a solid and washed with 2 ml of KHSO 4 The (R)-IOBA was diluted with 15% (15%) aqueous solution and extracted with 1-2 mL ethyl acetate. The organic phase was separated and concentrated. The oil was dried under reduced pressure and dissolved in isohexane:ethanol 1:1 (1 mL). From this solution, 250 μL was diluted with isohexane:ethanol 1:1 (1 mL) and analyzed by chiral LC-DAD. The resulting (R)-IOBA had an enantiomeric excess of 56.47%.
[0194] Example 4
[0195] A solution of (R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzoic acid (50 mg, 0.120 mmol) in 2-propanol (299 μl) with >99% ee was incubated with a solution of cesium hydroxide in 2-propanol (66.8 μl, 0.359 mmol) in a 1 ml conical vial. The mixture was heated to 90° C. overnight.
[0196] A 100 μL sample of the reaction mixture was concentrated to a solid and washed with 2 ml of KHSO 4 The (R)-IOBA was diluted with 15% (15%) aqueous solution and extracted with 1-2 mL ethyl acetate. The organic phase was separated and concentrated. The oil was dried under reduced pressure and dissolved in isohexane:ethanol 1:1 (1 mL). From this solution, 250 μL was diluted with isohexane:ethanol 1:1 (1 mL) and analyzed by chiral LC-DAD. The resulting (R)-IOBA had an enantiomeric excess of 56.47%.
[0197] Example 5
[0198] The flask was equipped with a condenser and a thermometer. 2-Propanol (6.67 ml) was charged into a flask, potassium hydroxide powder (0.671 g, 11.96 mmol) was dissolved in the solvent and (5R)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl)-2-methylbenzoic acid (1 g, 2.391 mmol) with 87.2% ee was added at 40°C. The mixture was heated to reflux. A clear orange solution was formed. After a while, a yellow solid material was precipitated. The suspension was further heated to reflux. A 50 μL sample of the suspension was treated as described in Example 1. The resulting (R)-IOBA had an enantiomeric excess of 0.8%.
[0199] As can be seen from Examples 1 to 5, the excess of (R)-IOBA contained in the obtained products is reduced. Therefore, it can be concluded that the molar amount of (S)-IOBA is increased by racemizing the starting mixture.
[0200] Example 6
[0201] In the 1L three-necked flask equipped with KPG stirring unit (IKA RW-16 basic type) and reflux condenser, load 2-propyl alcohol (200mL) and (5RS)-4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazole-3-yl)-2-methyl benzoic acid (100g, 239mmol).Add another portion of 2-propyl alcohol (250mL).Stir the mixture until all solid materials dissolve.(S)-1-amfetamine (21ml, 144mmol) is added rapidly with 1mL (first) and 20mL (second) portion of form by syringe.
[0202] The mixture was further stirred at room temperature for 75 minutes, after which a suspension was formed. The mixture was stirred at reflux temperature for 45 minutes. Heating was stopped and the suspension was slowly cooled to room temperature under stirring.
[0203] The suspension was filtered, and the colorless filter cake was washed 4 times with 100 mL of 2-propanol solution. The filter cake was dried under reduced pressure overnight.
[0204] Amount of isolated (S)-IOBA-(S)-1-phenylpropylammonium salt: 57.065 g (yield: 86.3%). Chiral LC analysis of an ammonium salt sample showed an enantiomeric excess of 95% for enantiomerically enriched (S)-IOBA without further crystallization.
[0205] Recycling steps:
[0206] The collected supernatant and washings from the crystallization step were concentrated to 400 mL. Powdered potassium hydroxide (27.916 g, 498 mmol) was added to the enantiomerically enriched (R)-IOBA solution and heated to reflux with stirring. A sample was taken from the reaction mixture and analyzed by chiral LC to determine the enantiomeric excess of (R)-IOBA. Heating was stopped when the residual enantiomeric excess of (R)-IOBA reached 2.4%.
[0207] The solvent was evaporated and 300 mL of water was added to the remaining IOBA-salt. Concentrated H 2 SO 4 (13.3 mL) in 65 mL of water. 2 SO 4 The aqueous suspension was set to pH = 2 by a solution of 1 x 200 mL of ethyl acetate (3.8 mL) in 18.5 mL of water. The aqueous suspension was extracted successively with 1 x 200 mL and 2 x 100 mL of ethyl acetate. The collected organic phases were washed twice with brine (100 mL) and purified by MgSO 4 After filtration, the organic solvent was evaporated to obtain IOBA as recovered solid material. Amount of IOBA after drying: 53 g, containing 7 wt% ethyl acetate.
Claims
1. Process for the racemization of a mixture containing (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1a) and (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1b) wherein the mixture has an enantiomeric excess of the compound according to formula (1a), the process comprising the steps of: (i) reacting the mixture with a basic compound in an organic solvent to obtain a reaction mixture, wherein the alkaline compound is selected from sodium hydroxide, potassium hydroxide, cesium hydroxide and mixtures thereof; wherein the organic solvent is 2-propanol; wherein step (i) is performed in the absence of a phase transfer catalyst.
2. The process according to claim 1, wherein the alkaline compound is potassium hydroxide.
3. The method according to claim 1, further comprising the following previous steps (a) reacting (5RS)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid with a compound of formula (2A), (2B) or (2C) wherein R is an alkyl group having 1 or 2 carbon atoms, Wherein X is Cl or Br; reacting in an organic solvent selected from alcohols having 2 to 5 carbon atoms, tetrahydrofuran, dioxane, toluene, ethyl acetate, and mixtures thereof to form a precipitate and a supernatant solution, and (b) separating from the precipitate a supernatant solution comprising a mixture of (5R)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1a) and (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid according to formula (1b).
4. The process according to claim 3, wherein the solvent in step (a) is selected from alcohols having 2 to 5 carbon atoms, dioxane, tetrahydrofuran and mixtures thereof.
5. The process according to claim 3, wherein the solvent in step (a) is 2-propanol.
6. The method according to claim 3, wherein in step (a), R of formula (2A) is methyl and the solvent is 2-propanol, or R of formula (2A) is ethyl and the solvent is 2-propanol.
7. The method according to claim 3, wherein the separation of the supernatant solution from step (a) from the precipitate in step (b) is performed by filtration.
8. The process according to claim 3, wherein the organic solvents in steps (a) and (i) are the same.
